GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gossamer Bio Inc (NAS:GOSS) » Definitions » Research & Development

Gossamer Bio (Gossamer Bio) Research & Development : $129.87 Mil (TTM As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Gossamer Bio Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Gossamer Bio's Research & Development for the three months ended in Mar. 2024 was $32.39 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was $129.87 Mil.

Gossamer Bio Research & Development Historical Data

The historical data trend for Gossamer Bio's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gossamer Bio Research & Development Chart

Gossamer Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial 143.40 160.85 170.27 170.92 135.30

Gossamer Bio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.80 36.31 31.20 29.97 32.39

Gossamer Bio Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $129.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gossamer Bio  (NAS:GOSS) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Gossamer Bio Research & Development Related Terms

Thank you for viewing the detailed overview of Gossamer Bio's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Gossamer Bio (Gossamer Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gossamer Bio Inc (NAS:GOSS) » Definitions » Research & Development
Comparable Companies
ABSI TSVT DSGN CDT ACRV SEER CYT BTAI TRVI CDXS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
4GB:Germany
Address
3013 Science Park Road, Suite 200, San Diego, CA, USA, 92121
Website
https://www.gossamerbio.com
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Executives
Sandra Milligan director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Bryan Giraudo officer: Chief Financial Officer 7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560
Richard Aranda officer: Chief Medical Officer 3013 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Faheem Hasnain director, officer: Executive Chairman 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Waage Christian officer: EVP & General Counsel RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Caryn Peterson officer: EVP, Regulatory Affairs 3013 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Laura Carter officer: Chief Scientific Officer 3013 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Luisa Salter-cid officer: Chief Scientific Officer C/O GOSSAMER BIO, INC., 3013 SCIENCE PARK ROAD, SUITE 200, SAN DIEGO CA 92121
Jakob Dupont officer: Chief Medical Officer C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Sheila Gujrathi director, officer: President & CEO 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Omega Fund V Gp, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V Gp Manager, Ltd. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Otello Stampacchia director, 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Russell J. Cox director C/O JAZZ PHARMACEUTICALS, PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2